Table 1.

Results of phase 1/2 trials of 3- and 4-drug combination induction regimens in multiple myeloma

Results of phase 1/2 trials of 3- and 4-drug combination induction regimens in multiple myeloma

RVDD indicates RVD + pegylated liposomal doxorubicin; VDC, bortezomib + dexamethasone + intravenous cyclophosphamide on days 1 and 8 of a 21 day cycle; VDC-mod, VCD + IV cyclophosphamide on day 15; and VDR, bortezomib + dexamethasone + lenalidomide.

*CR only.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal